JINAN, China, Dec. 25, 2024 /PRNewswire/ -- During the 66th Annual Meeting of the American Society of Hematology (ASH) held in San Diego from December 7 to 10, preliminary results from the first human trial of QLS32015, a novel anticancer drug developed by Qilu Pharmaceutical for treating relapsed/refractory multiple myeloma (RRMM), were unveiled (Poster Number: 1990). The findings demonstrated that QLS32015 showed excellent anti-tumor activity and was well tolerated by patients with RRMM.
QLS32015, a novel humanized IgG1 T-cell retargeting bispecific antibody, targets both GPRC5D, a G protein-coupled receptor class C group 5 member D, and CD3. By bridging CD3-expressing T cells and GPRC5D-expressing tumor cells, QLS32015 facilitates T-cell-mediated destruction of cancer cells. Instead of relying on the conventional major histocompatibility complex (MHC) and specific T-cell receptor (TCR) binding pathways, this process creates an immune synapse that activates T cells, triggering them to attack and kill tumor cells. [1-2]
This study is an open-label, dose-escalation/expansion Phase I clinical trial (NCT05920876), aiming to assess the safety of QLS32015 in patients with RRMM while offering preliminary insights into its efficacy. The study is led by Prof. Lugui Qiu from the Institute of Hematology and Blood Diseases Hospital at the Chinese Academy of Medical Sciences.
The study enrolled patients with RRMM who had either progressed on or shown intolerance to existing treatments. These patients received QLS32015 as monotherapy, administered subcutaneously at doses ranging from 2 to 200 μg/kg, either weekly or biweekly. During the Phase Ia dose-escalation phase, the primary endpoints were to identify the dose-limiting toxicities (DLT), the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D). The study design employed a combination of accelerated titration and Bayesian optimal interval strategies.
As of August 31, 2024, a total of 13 patients had been enrolled in the trial. The median age among these participants was 61 years, and they had undergone a median of 3 prior lines of therapy (range, 1 to 8). Notably, 76.9% of the patients had received at least triple therapy, which included proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies. Additionally, 23.1% of the participants had been treated with B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy.
In terms of safety, one DLT was observed at the 54 μg/kg dose level, but the MTD was not reached. Treatment-related adverse events (TRAEs) were reported in all patients. The most common TRAE was cytokine release syndrome (CRS), occurring at grades 1 or 2 in all patients, with a median duration of 2.1 days. The most common grade ≥3 TRAEs were hematological toxicities, including lymphopenia (92.3%) and thrombocytopenia (61.5%). Most non-hematological TRAEs were grade 1 or 2. Importantly, no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were reported, and there were no TRAEs that led to treatment discontinuation or death.
As of the data cut-off, 12 out of the 13 enrolled patients had undergone at least one assessment of efficacy. The objective response rate (ORR), assessed according to the International Myeloma Working Group (IMWG) criteria, was 76.9% (10/13). Among these patients, two (15.4%) achieved complete response (CR), three (23.1%) reached very good partial response (VGPR), and five (38.5%) attained partial response (PR).
The findings suggest that QLS32015 has a tolerable safety profile and shows promising remission rates among RRMM patients. The dose-escalation study is still in progress. DLT, MTD, and RP2D are to be determined.
References:
1. Li J, et al. 2017;31(3):383-395.
2. Velasquez MP, et al. Blood. 2018;131(1):30-38.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting
Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting
Revealing the Top 15 Searched Keywords in Asia
TAIPEI, Dec. 25, 2024 /PRNewswire/ -- SWAG, Taiwan's largest adult livestreaming platform, often known as the "Pornhub of Asia," has released the 2024 SWAG Recap today. The report dives into the world of trending adult content, the year's top searched keywords, and even the income of creators, sparing no details. According to the data, the top searched keyword on SWAG in 2024 was "Vietnam." Meanwhile, two Taiwanese creators—former Army Chief Counselor "Neinei" and former Sea Dragon Frogman 177—landed in the 3rd and 6th positions as the most searched keywords thanks to their enormous social media buzz. The hashtag with the most clicks went to "Big Boobs."
In this year's top searched keyword ranking, "Vietnam" and Vietnamese creator Rosa (@rosababyvip) dominated the top two spots with overwhelming search volume, highlighting the loyalty of Vietnamese enjoyers of SWAG. Meanwhile, keywords like "Ex-Army Chief Counselor Neinei" and "Sea Dragon Frogman 177" maintained high visibility throughout the year, landing them in 3rd and 6th places, respectively.
Analyzing average daily login time by users from different countries, SWAG users spent 15 minutes and 56 seconds per session on average globally, 49 seconds longer than last year. Taiwan emerged as the undisputed champion with an average daily login time of 16 minutes and 21 seconds, the only country above the platform average. On the flip side, Japanese users clocked in at just 11 minutes and 25 seconds, becoming the quickest to reach post-nut clarity. Notably, Vietnamese users soared from last year's last place to the 4th longest with their online duration time, surpassing users from Singapore and the U.S.
Among SWAG's nearly 200 hashtags, "Big Boobs" reclaimed its crown from last year's champion, "Schoolgirl," becoming the most searched hashtag of the year. "Schoolgirl" fell to 4th, edged out by "Gangbang." Surprisingly, the long-beloved tag "Creampie" dropped to its record-low position, only ranking 9th.
SWAG noted that nearly 5,000 new creators joined this year, with 40% hailing from Vietnam, making it the country with the most new creators, followed by Taiwan. Among the talents, luna (@rouav) and Jolly (@jollyntr) were crowned as the most popular creator and best newcomer respectively! After a brief hiatus, Luna made a strong comeback by captivating fans with her "natural melons," "S-line waist," "perky booties," and "flawless legs." Her popularity skyrocketed by 891 spots, earning her the title of SWAG's Most Popular Creator 2024. The best newcomer, Jolly, who only joined SWAG less than a year ago, gained immense popularity for her housewife aesthetic and NTR-themed content. Fans of the married lady buzzed over her livestreams and videos, where her husband reportedly has been watching helplessly behind the camera, further fueling her meteoric rise.
In other creator data, SWAG's "Fan Following Clock" is ticking faster than ever! On average, a creator gains a new follower every 5.7 seconds on the platform. Additionally, 8.8% of new creators earn USD 30,000 in less than four months, with Betty (@bettyqueen) achieving this milestone in just three weeks, making her the fastest-earning newcomer of 2024.
Does SWAG make creators rich? The numbers prove everything. This year, Shirley (@shirleybebe) posted a story, which was unlocked by over 3,000 users within 48 hours, earning her approximately $1,500 instantly as the post became the most profitable story of 2024. Best Newcomer Jolly also delivered impressive results. After debuting in May, one of her long videos attracted over 2,000 viewers, earning her $17,000 just from that one single upload.
When it comes to SWAG's most lucrative money-making features, livestreaming and private messaging definitely top the list. For example, when Grape (@stellajs) hosted her birthday livestream this year, she generated USD 37,000 in just three hours. Meanwhile, Nini Baby (@ninibaby), well-known for her private chats, sent 380,000 text messages to users this year, receiving 85,000 replies and countless chat gifts. Her private messaging income alone earned a staggering USD 490,000 in revenue, a 17% increase from last year, securing her throne as SWAG's Queen of private chat.
《2024 SWAG Recap》: https://swag.live/blog/en/swag_2024_recap/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
SWAG, Asia's Largest Adult Content Platform, Releases 2024 Annual Report
